– Reuters
JP Morgan Maintains Underweight on HBT Finl, Lowers Price Target to $19
JP Morgan analyst Anthony Elian maintains HBT Finl (NASDAQ:HBT) with a Underweight and lowers the price target from $19.5 to $19.
Related Posts
Morgan Stanley Upgrades Sealed Air to Overweight, Announces $79 Price Target
Morgan Stanley analyst Angel Castillo upgrades Sealed Air (NYSE:SEE) from Equal-Weight to Overweight and announces $79 price target.
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $50
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $36 to $50.
Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to $54
Morgan Stanley analyst Drew Ranieri maintains NuVasive (NASDAQ:NUVA) with a Equal-Weight and lowers the price target from $62 to $54.